The Indian Journal of Sexually Transmitted Diseases and AIDS, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, serves as a vital platform for disseminating research and knowledge in the fields of sexually transmitted infections and HIV/AIDS management. With ISSN 2589-0557 and E-ISSN 2589-0565, this journal aims to bridge the gap in public health and clinical research by providing peer-reviewed articles that cover a range of topics from epidemiology to therapeutic advancements. Despite its status with an impact factor in the lower quartiles across relevant categories, including Q3 in Dermatology, Q4 in Infectious Diseases, and Q4 in Public Health, it holds potential for growth and greater visibility within the academic community. The journal's scope spans critical insights and innovative approaches in managing sexually transmitted diseases, and it is committed to fostering scholarly discourse among its readership consisting of researchers, health professionals, and students alike. As it converges from 2018 to 2024, the Indian Journal of Sexually Transmitted Diseases and AIDS continues to underscore the importance of addressing pressing health issues in India and beyond, while offering an accessible resource for those dedicated to this vital field.

HIV Medicine is a prestigious journal published by Wiley that stands at the forefront of research in the fields of health policy, infectious diseases, and pharmacology, with a commendable impact factor reflected in its Q1 rankings for 2023. Established in 1999 and set to converge its expertise through 2024, this journal plays a critical role in advancing the understanding and treatment of HIV and related health challenges. It is esteemed for its rigorous peer-review process and its contributions to both clinical and policy-oriented discussions surrounding HIV medicine. With a broad international readership, it serves as a vital resource for researchers, healthcare professionals, and students committed to fighting the global HIV epidemic. Although not open access, its vital insights are indispensable for anyone involved in infectious disease research and healthcare policy. Articles published in HIV Medicine shape global health strategies and influence the future of HIV research, making it a must-read for those dedicated to this crucial field.

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a leading peer-reviewed journal dedicated to advancing the field of infectious diseases, particularly focusing on tuberculosis and other mycobacterial infections. Published by ELSEVIER in the United Kingdom with an impressive open access model since 2015, this journal aims to provide a platform for the dissemination of high-quality research, clinical findings, and innovative methodologies in the management of mycobacterial diseases. With a commendable impact, the journal currently holds a Q2 ranking in multiple categories including Infectious Diseases and Pulmonary and Respiratory Medicine, reflecting its influence in the academic community. The journal is dedicated to serving researchers, healthcare professionals, and students by offering access to essential information that can improve patient outcomes and enhance public health strategies. As the field of mycobacterial diseases continues to evolve, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases remains a crucial resource for those seeking to remain at the forefront of research and clinical practice.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

Welcome to AIDS PATIENT CARE AND STDS, a leading journal dedicated to the comprehensive exploration of clinical practices, research advancements, and public health strategies centered around HIV/AIDS and sexually transmitted diseases. Published by Mary Ann Liebert, Inc., this esteemed journal has been at the forefront of disseminating critical findings since 1996, contributing to a robust understanding of the complexities surrounding these global health issues. With an impressive impact factor reflected in its 2023 Q1 quartile rankings in both Infectious Diseases and Public Health, Environmental and Occupational Health, the journal stands out among its peers, ranking at the 95th percentile for Public Health and 91st percentile in Infectious Diseases. Researchers, healthcare professionals, and students will benefit from its rich content, comprehensive studies, and critical reviews that aim to improve care practices and health outcomes. With a clear commitment to fostering knowledge and collaboration in the field, AIDS PATIENT CARE AND STDS is an essential resource for those dedicated to combating these pressing health challenges.

Virology, published by Academic Press Inc. Elsevier Science, is a prominent journal dedicated to advancing the knowledge and understanding of viral biology and pathogenesis since its inception in 1955. With a distinguished impact factor and recognized as a Q2 journal in the field of Virology for 2023, it ranks 38 out of 80 in the Scopus database for Immunology and Microbiology, placing it in the 53rd percentile among similar publications. This esteemed journal provides a platform for groundbreaking research, critical reviews, and comprehensive studies that contribute to our global understanding of viruses and their impact on health and disease. Although currently not an open-access journal, it remains accessible to a wide audience of researchers, professionals, and students who are keen to explore the latest advancements in virological research. The journal's scope encompasses a diverse range of topics, ensuring that it serves as an essential resource for anyone engaged in virology and related biomedical fields.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

AIDS Research and Treatment is a premier open access journal published by HINDAWI LTD, dedicated to advancing the understanding and treatment of HIV/AIDS and related conditions. Launched in 2010, the journal has established itself as a vital resource for researchers, healthcare professionals, and students in the fields of Dermatology, Immunology, Infectious Diseases, and Public Health. With a notable 2023 impact factor reflected in its Q2 and Q3 quartile rankings across key medical categories, the journal plays a critical role in disseminating high-quality research and fostering innovation in the prevention and treatment of AIDS. It provides a wide range of open access options, enabling easier dissemination and increased visibility of research findings globally. As the landscape of HIV/AIDS research continues to evolve, AIDS Research and Treatment remains at the forefront, ensuring crucial insights and developments are shared to enhance public health outcomes.

Retrovirology is a prominent open-access journal published by BMC since 2004, dedicated to the field of retroviral research. With a strong focus on advancing knowledge in both infectious diseases and virology, this interdisciplinary journal has achieved a commendable ranking of Q2 in its respective categories as of 2023, reflecting its significant contribution to the scientific community. Hosted in the United Kingdom, Retrovirology serves a global audience of researchers, professionals, and students, making vital research accessible to all without barriers. The journal's emphasis on high-quality peer-reviewed articles supports the dissemination of groundbreaking findings that could shape the future of virology and related fields. With an impressive Scopus ranking, including a percentile of 65th in Medicine: Infectious Diseases, it stands out as a valuable resource for those committed to understanding and combating viral diseases. Retrovirology continues to be an essential platform for innovative research, with its open-access model ensuring that transformational science reaches the widest possible audience.